I have had 2 Cape Verdean patients over the past few years who have developed gastric cancer.\u00a0 Several months ago I met with a Cape Verdean doctor who confirmed that gastric cancer was relatively common in Cape Verde.\u00a0 Gastric cancer screening in general does not make sense in the United States given the low prevalence of gastric cancer.\u00a0 However, many of our patients come from countries with much higher prevalence, prompting this review.\u00a0 I am posting about this\u00a0 generally because many of us see patients coming from high prevalence countries.<\/p>\n
Most of the data is not great.\u00a0 There has been mass population screening in Japan since 1983\u00a0 for individuals over 40, where gastric cancer is the leading cause of cancer death.\u00a0 A systematic review was done by the Japanese Health Ministry (see doi:10.1093\/jjco\/hyn017<\/strong>), which only found 10 studies directly related to screening, none of which were randomized controlled trials — only case-control or cohort studies.\u00a0 They noted in Japan there has been an overall decrease of gastric cancer mortality from 1980 to 2003, from\u00a069.9 to 34.5 per 100,000 in males, and 34.1 down to 13.2 per 100,000 in females.\u00a0 In their systematic review they found that the best evidence was for barium studies (the most widely used intervention), finding a 40-60% decrease in gastric cancer mortality and a 5 year survival rate of 74-80% for those screened versus 46-56% for the non-screened group.\u00a0 They found that the data were more mixed and less compelling for endoscopy screening, or blood tests for serum pepsinogen or Helicobacter pylori antibody.\u00a0 A cohort study in Korea, looking retrospectively at 2485 patients with gastric adenocarcinoma, found that those screened at 4-5 year intervals had a higher risk for gastric cancer than those screened at 2-3 year intervals. Those at the highest risk, people with a family history of gastric cancer and those in their 60s, were found to have a higher stage of gastric cancer when the intervention was performed every 3 years as opposed to annually.\u00a0 This all led to the recommendation for screening every 2 years by upper GI series or endoscopy for individuals over 40 years old.\u00a0 Since none of these studies were RCTs, there may be significant biases (lead time bias, length bias, etc.)<\/p>\n There was an RCT in 2004 on H. pylori eradication as a means to prevent gastric cancer ( see JAMA 2004; 291: 187-194<\/strong>).\u00a0 In this Chinese trial (from Fujian Province, where mortality rate from gastric cancer is 153\/100K, and where they have found a 2-4 fold increase in gastric cancer in those H pylori positive) 1630 healthy carriers of H. pylori were enrolled, of whom 988 did not have any precancerous lesions on endoscopy (gastric atrophy, intestinal metaplasia, or gastric dysplasia) at study entry.\u00a0 The H. pylori status was documented by the endoscopic exam.\u00a0 Patients were randomly assigned H pylori therapy (a two-week course of omeprazole 20 mg, amoxicillin\/clavulanate 750 mg, and metronidazole 400 mg, all twice a day) versus placebo, and followed 7.5\u00a0 years.\u00a0 Results:<\/p>\n \u00a0–76.4% of patients given triple therapy for H pylori were\u00a0 successfully treated, per urea breath test.\u00a0 Those who failed treatment were given quad therapy –the ultimate eradication rate was 83.7% so, what is one to do in the United States?\u00a0 At this point, given the lack of large RCTs, it seems to me to be hard to recommend an aggressive screening program with either upper GI radiography or endoscopy.\u00a0 However, given the very high prevalence of H pylori infection in many of these patients (including our Cape Verdean patients), and given the known association of H. pylori infection and gastric cancer at least in some high prevalence countries, and given the RCT from Fujian Province,\u00a0 I personally think that it would be appropriate to screen and treat patients for H pylori infection, using the H. pylori antibody as a reasonable marker of infection.<\/p>\n geoff<\/p>\n","protected":false},"excerpt":{"rendered":" Gastric Cancer Screening\/Prevention […]<\/p>\n
\n–Primary outcome (incidence of gastric cancer during followup): No difference, with 7 cases in the H. pylori treatment group and 11 cases in the placebo.
\n–Secondary outcome (incidence of gastric cancer, comparing those with or without precancerous lesions): In those without precancerous lesions none developed gastric cancer in those treated for H. pylori, 6 did the placebo group, statistically significant.\u00a0 Of note, the cumulative incidence of cancer in the placebo group was increasing dramatically\u00a0after about 6 years, whereas those were H. pylori negative remained without cancer (ie very impressive splaying of the curves).
\n–Smoking and older age were independent risk factors for the development of gastric cancer, with smoking, having a hazards, ratio of 6.2.<\/p>\n